Inhaled nano -and microparticles for drug delivery

Global Cardiology Science and Practice

Volumn 2015, Issue 1, 2015, Pages

  El Sherbiny, Ibrahim M ^a   El Baz, Nancy M ^a   Yacoub, Magdi H ^b  

^a 6th of October City   (Egypt)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Bioavailability; Liposomes; Micelles; Particulate based drug delivery system; Polymeric micro nanoparticles; Pulmonary clearance mechanisms; Pulmonary delivery; Solid lipid nanoparticles

Indexed keywords

ADRENALIN; BUDESONIDE; CHITOSAN; CICLESONIDE; CYCLODEXTRIN; DOCETAXEL; ENBUCRILATE; INSULIN; ITRACONAZOLE; LIPOSOME; PENICILLIN DERIVATIVE; PIG INSULIN; POLYBUTYLCYANOACRYLATE NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID; SALMETEROL; SOLID LIPID NANOPARTICLE; STEROID; THEOPHYLLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ASTHMA; BODY SURFACE; CHEMICAL STRUCTURE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; ENZYMATIC DEGRADATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; METERED DOSE INHALER; MICELLE; MUCOCILIARY CLEARANCE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; REVIEW;

EID: 85067261496     PISSN: None     EISSN: 23057823     Source Type: Journal    
DOI: 10.5339/gcsp.2015.2     Document Type: Review

References (79)

1. Weers JG, Bell J, Chan H-K, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? Journal of aerosol medicine and pulmonary drug delivery. 2010;23(S2):S-5-S-23.
2. Courrier H, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier Systems. 2002;19(4-5).
3. Ungaro F, d'Angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered PLGA nano-and micro-carriers for pulmonary delivery: challenges and promises. Journal of Pharmacy and Pharmacology. 2012;64(9):1217-35.
4. Marieb EN, Hoehn K. Human anatomy & physiology: Pearson Education; 2007.
5. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. International journal of nanomedicine. 2008;3(1):1.
6. Paranjpe M, Müller-Goymann CC. Nanoparticle-Mediated Pulmonary Drug Delivery: A Review. International journal of molecular sciences. 2014;15(4):5852-73.
7. McCorry LK. Essentials of human physiology for pharmacy: CRC Press; 2004.
8. The Respiratory System.2012[2 July]; Available from: http://www.nhlbi.nih.gov/health/healthtopics/topics/hlw/system.html
9. El-Sherbiny IM, Villanueva DG, Herrera D, Smyth HD. Overcoming lung clearance mechanisms for controlled release drug delivery.Controlled Pulmonary Drug Delivery: Springer; 2011. p. 101-26.
10. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim K-J, et al. The particle has landed - characterizing the fate of inhaled pharmaceuticals. Journal of aerosol medicine and pulmonary drug delivery. 2010;23(S2):S-71-S-87.
11. Hogg J. Response of the lung to inhaled particles. The Medical journal of Australia. 1985;142(13):675-8.
12. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Eirefelt S, Ekelund K, et al. Pulmonary drug metabolism, clearance, and absorption.Controlled Pulmonary Drug Delivery: Springer; 2011. p. 21-50.
13. Oberdörster G. Lung clearance of inhaled insoluble and soluble particles. Journal of Aerosol Medicine. 1988;1(4):289-330.
14. Parkinson A. Biotransformation of xenobiotics: McGraw-Hill New York; 2001.
15. Patton JS. Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery Reviews. 1996;19(1):3-36.
16. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nature Reviews Drug Discovery. 2007;6(1):67-74.
17. Liao X, Wiedmann TS. Solubilization of cationic drugs in lung surfactant. Pharmaceutical research. 2003;20(11):1858-63.
18. Wiedmann T, Bhatia R, Wattenberg L. Drug solubilization in lung surfactant. Journal of controlled release. 2000;65(1):43-7.
19. Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. International journal of nanomedicine. 2009;4:299.
20. Beck-Broichsitter M, Gauss J, Packhaeuser CB, Lahnstein K, Schmehl T, Seeger W, et al. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. International journal of pharmaceutics. 2009;367(1):169-78.
21. Labiris N, Dolovich M. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. British journal of clinical pharmacology. 2003;56(6):588-99.
22. Davies C, Muir D. Deposition of inhaled particles in human lungs. 1966.
23. Jain KK. Drug delivery systems-an overview.Drug Delivery Systems: Springer; 2008. p. 1-50.
24. T. V. Thulasiramaraju BTK, M. Nikilesh Babu. Pulmonary Drug delivery systems-an overview. 2013:16-34.
25. Yang W, Peters JI, Williams III RO. Inhaled nanoparticles - a current review. International journal of pharmaceutics. 2008;356(1):239-47.
26. Boucher R. Regulation of airway surface liquid volume by human airway epithelia. Pfluegers Archiv. 2003;445(4):495-8.
27. Grenha A, Grainger CI, Dailey LA, Seijo B, Martin GP, Remuñán-López C, et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. European journal of pharmaceutical sciences. 2007;31(2):73-84.
28. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharmaceutical research. 2008;25(8):1815-21.
29. Usmani OS, Biddiscombe MF, Underwood SR, Barnes PJ. Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator. Journal of Nuclear Medicine. 2004;45(1):69-73.
30. Makino K. Pulmonary drug delivery system. [Available from: http://www.tus.ac.jp/rist/lab/introduction/2research-centers/906.html
31. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. Journal of Applied Physiology. 1998;85(2):379-85.
32. Ehrhardt C, Fiegel J, Fuchs S, Abu-Dahab R, Schaefer U, Hanes J, et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. Journal of Aerosol Medicine. 2002;15(2):131-9.
33. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards D. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proceedings of the National Academy of Sciences. 2002;99(19):12001-5.
34. El-Sherbiny IM, McGill S, Smyth HD. Swellable microparticles as carriers for sustained pulmonary drug delivery. Journal of pharmaceutical sciences. 2010;99(5):2343-56.
35. El-Sherbiny IM, Smyth HD. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery:(I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. International journal of pharmaceutics. 2010;395(1):132-41.
36. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(13):4930-4.
37. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharmaceutical research. 2009;26(1):244-9.
38. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery. 2003;2(3):214-21.
39. Suzuki Y, Yamaguchi T. Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release. Agents and actions. 1993;38(1):32-7.
40. Surendrakumar K, Martyn G, Hodgers E, Jansen M, Blair J. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. Journal of controlled release. 2003;91(3):385-94.
41. Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. Journal of controlled release. 1998;51(2):143-52.
42. Hickey AJ. Pharmaceutical inhalation aerosol technology: CRC Press; 2003.
43. Niven RW, Whitcomb KL, Shaner L, Ip AY, Kinstler OB. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharmaceutical research. 1995;12(9):1343-9.
44. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly (ethylene glycol)(DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. International journal of nanomedicine. 2013;8:275.
45. Jaafar-Maalej C, Elaissari A, Fessi H. Lipid-based carriers: manufacturing and applications for pulmonary route. Expert opinion on drug delivery. 2012;9(9):1111-27.
46. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. Journal of controlled release. 1993;24(1):209-23.
47. Lasic DD. Liposomes in gene delivery: CRC press; 1997.
48. Bai S, Gupta V, Ahsan F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. european journal of pharmaceutical sciences. 2009;38(2):165-71.
49. Kaur G, Narang R, Rath G, Goyal AK. Advances in pulmonary delivery of nanoparticles. Artificial Cells, Blood Substitutes and Biotechnology. 2012;40(1-2):75-96.
50. Saari SM, Vidgren MT, Koskinen MO, Turjanmaa ViM, Waldrep JC, Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. CHEST Journal. 1998;113(6):1573-9.
51. Arppe J, Vidgren M, Waldrep J. Pulmonary pharmacokinetics of cyclosporin A liposomes. International journal of pharmaceutics. 1998;161(2):205-14.
52. Poyner E, Alpar H, Almeida A, Gamble M, Brown M. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. Journal of controlled release. 1995;35(1):41-8.
53. Gibbons AM, McElvaney NG, Taggart CC, Cryan S-A. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. Journal of microencapsulation. 2009;26(6):513-22.
54. Shahiwala A, Misra A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech. 2004;5(1):96-100.
55. Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics. 2013;5(4):542-69.
56. Beck-Broichsitter M, Ruppert C, Schmehl T, Guenther A, Betz T, Bakowsky U, et al. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine: Nanotechnology, Biology and Medicine. 2011;7(3):341-50.
57. Nassimi M, Schleh C, Lauenstein H, Hussein R, Hoymann H, Koch W, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. European Journal of Pharmaceutics and Biopharmaceutics. 2010;75(2):107-16.
58. Nassimi M, Schleh C, Lauenstein H-D, Hussein R, Lübbers K, Pohlmann G, et al. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhalation toxicology. 2009;21(S1):104-9.
59. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. International journal of pharmaceutics. 2008;356(1):333-44.
60. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. International journal of pharmaceutics. 2008;361(1):177-88.
61. MuÈller RH, MaÈder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000;50(1):161-77.
62. Li Y-Z, Sun X, Gong T, Liu J, Zuo J, Zhang Z-R. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharmaceutical research. 2010;27(9):1977-86.
63. Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2014;86(1):7-22.
64. Illum L, Watts PJ. Polysaccharide microspheres for the pulmonary delivery of drugs. Google Patents; 1997.
65. Feng S-S, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science. 2003;58(18):4087-114.
66. Williams III RO, Barron MK, José Alonso M, Remuñán-López C. Investigation of a pMDI system containing chitosan microspheres and P134a. International journal of pharmaceutics. 1998;174(1):209-22.
67. Wang H, Xu Y, Zhou X. Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: In vitro and in vivo evaluation. International journal of molecular sciences. 2014;15(3):3519-32.
68. Doan T, Olivier J. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. International journal of pharmaceutics. 2009;382(1):61-6.
69. Kaye RS, Purewal TS, Alpar HO. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. Journal of pharmaceutical sciences. 2009;98(11):4055-68.
70. Marsh D, Bartucci R, Sportelli L. Lipid membranes with grafted polymers: physicochemical aspects. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2003;1615(1):33-59.
71. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jørgensen K. Drug delivery by phospholipase A〈sub〉 2〈/sub〉 degradable liposomes. International journal of pharmaceutics. 2001;214(1):67-9.
72. Lavasanifar A, Samuel J, Kwon GS. Poly (ethylene oxide)-block-poly (l-amino acid) micelles for drug delivery. Advanced Drug Delivery Reviews. 2002;54(2):169-90.
73. Gaber NN, Darwis Y, Peh K-K, Tan YT-F. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. Journal of nanoscience and nanotechnology. 2006;6(9-10):3095-101.
74. Duchêne D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting: application to nanoparticles. Advanced Drug Delivery Reviews. 1999;36(1):29-40.
75. Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. Journal of controlled release. 1999;62(1):263-8.
76. Yang W, Chow KT, Lang B, Wiederhold NP, Johnston KP, Williams III RO. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. european journal of pharmaceutical sciences. 2010;39(5):336-47.
77. Tolman JA, Nelson NA, Son YJ, Bosselmann S, Wiederhold NP, Peters JI, et al. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. European Journal of Pharmaceutics and Biopharmaceutics. 2009;72(1):199-205.
78. Ungaro F, d'Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, Quaglia F, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs. Journal of controlled release. 2009;135(1):25-34.
79. Jalalipour M, Najafabadi AR, Gilani K, Esmaily H, Tajerzadeh H. Effect of dimethyl-β-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. Journal of pharmaceutical sciences. 2008;97(12):5176-85.